Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6299971 | 0.85 | BMPR1B (0.37) | LMNAGAAGFERPOLBDRD2 | |
| SCHEMBL6300407 | 0.84 | LMNA (0.43) | LMNAGAAGFERPOLBDRD2 | |
| SCHEMBL6300067 | 0.83 | HTR7 (0.40) | LMNAGAAPOLBDRD2DRD4 | |
| SCHEMBL6849564 | 0.83 | CHRM2 (0.39) | POLBDRD2DRD4CHRM2CHRM4 | |
| SCHEMBL6302300 | 0.82 | POLB (0.65) | GAAPOLBDRD2DRD4CHRM2 | |
| SCHEMBL21257673 | 0.82 | HRH1 (0.56) | LMNADRD2DRD4CHRM2CHRM4 | |
| SCHEMBL28464729 | 0.81 | GSK3A (0.42) | ATAD2LMNAPOLBDRD2DRD4 | |
| SCHEMBL3425056 | 0.80 | NPSR1 (0.57) | LMNAGAAALDH1A1SMN1; SMN2GSK3B | |
| SCHEMBL30382092 | 0.80 | HTR7 (0.53) | ATAD2GAADRD2DRD4DRD3 | |
| SCHEMBL5113192 | 0.80 | HTR7 (0.53) | ATAD2GAADRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3782996-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-04-10 | — | — | EP | disclosed |
| US-20230047296-A1 | Nrf2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| US-20230047296-A1 | Nrf2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| EP-3782996-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-02-24 | — | — | EP | disclosed |
| EP-3782996-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-02-24 | — | — | EP | disclosed |
| EP-3307739-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| EP-3307739-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| US-10604509-B2 | Nrf2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-31 | — | — | US | disclosed |
| US-10604509-B2 | Nrf2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-31 | — | — | US | disclosed |
| US-20200079759-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2020-03-12 | — | — | US | disclosed |
| US-20180179187-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
| US-20180179187-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
| US-20180179187-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
| WO-2016202253-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-22 | — | — | WO | disclosed |
| US-6838455-B2 | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2005-01-04 | — | — | US | disclosed |
| US-6774125-B2 | TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. | 2004-08-10 | — | — | US | disclosed |
| US-6696438-B2 | AMYLOID PRECURSOR PROTEIN ANTAGONISTS, 3-((N'-(3-PYRIDINOYL)-L -ALANINYL)-AMINO-3-METHYL-4,5,6,7-TETRAHYDRO-2H-3-BENZAZEPIN-2-ONE, USED FOR PROPHYLAXIS OF NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. | 2004-02-24 | — | — | US | disclosed |
| US-6552013-B1 | For therapy of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2003-04-22 | — | — | US | disclosed |
| US-6528505-B1 | Treating Alzheimer's disease;5-(S)-(N'-(L-prolyl)-L-alaninyl)-amino-7-methyl-5,7-di hydro-6H- dibenz(b,d)azepin-one | ELAN PHARMACEUTICALS, INC. | 2003-03-04 | — | — | US | disclosed |
| US-6509331-B1 | Bicyclic amides such as 5-('-(2S-hydroxy-3-methylbutyrl)-2S-aminopropyl)amino-7-methyl-5,7-dihydro -6H-dibenz(b,d)azepin-6-one | ELAN PHARMACEUTICALS, INC. | 2003-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179187-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | ATAD2 1407/4885LMNA 2563/4885GAA 2261/4885 |
| US-10604509-B2 | Nrf2 regulators | NFE2L2, KEAP1, NQO1 | ATAD2 1407/4885LMNA 2563/4885GAA 2261/4885 |
| US-20230047296-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | ATAD2 1445/4885LMNA 3312/4885GAA 2150/4885 |
| US-20200079759-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | ATAD2 1445/4885LMNA 3312/4885GAA 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.